Scientists have identified the presence of cancer-suppressing cells in pancreatic cancer

October 07, 2019

A research team led by Nagoya University has revealed that cells containing a protein called Meflin have a role in restraining the progression of pancreatic cancer, a type of cancer that is hard to treat with traditional anti-cancer drugs. The team has also shown that cancer progression can be limited by artificially increasing the amount of this protein in the cells. These findings could lead to the development of new therapies against pancreatic cancer. This study was published online in Cancer Research on Aug 22, 2019.

Cancer cells are surrounded by stromal cells, which include fibroblasts. Fibroblasts are considered to divide into at least two populations: those promoting cancer progression and those restraining it. However, the nature of cancer-restraining fibroblasts remained unknown due to the lack of specific markers for this population, while various markers of cancer-promoting fibroblasts have been identified.

To identify a marker of the cancer-restraining fibroblasts, a team led by Professor Masahide Takahashi and Associate Professor Atsushi Enomoto at the Department of Pathology in the Graduate School of Medicine, Nagoya University, conducted studies on fibroblasts, which exist in large numbers around pancreatic cancer cells, and identified the presence of a protein called Meflin. The team focused on this protein and revealed, based on studies of tissues from 71 pancreatic cancer patients, that patients who had a larger amount of Meflin experienced slower cancer progression. The team's experiments using mice also showed that pancreatic cancer in mice that had no Meflin progressed faster. Thus, they concluded that Meflin is a marker of cancer-restraining fibroblasts.

The study also showed that administration of vitamin D to fibroblasts helped to increase the amount of Meflin in the cells and that the progression of pancreatic cancer could be restrained by artificially increasing this protein. Professor Takahashi says, "We hope to develop drugs that increase Meflin so as to create new therapies against pancreatic cancer, a type of cancer that is hard to treat with traditional anti-cancer drugs."
-end-
The article, "Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis," was published in Cancer Research at DOI:10.1158/0008-5472.CAN-19-0454.

Authors: Yasuyuki Mizutani, Hiroki Kobayashi, Tadashi Iida, Naoya Asai, Atsushi Masamune, Akitoshi Hara, Nobutoshi Esaki, Kaori Ushida, Shinji Mii, Yukihiro Shiraki, Kenju Ando, Liang Weng, Seiichiro Ishihara, Suzanne M. Ponik, Matthew W. Conklin, Hisashi Haga, Arata Nagasaka, Takaki Miyata, Makoto Matsuyama, Tomoe Kobayashi, Tsutomu Fujii, Suguru Yamada, Junpei Yamaguchi, Tongtong Wang, Susan L. Woods, Daniel L. Worthley, Teppei Shimamura, Mitsuhiro Fujishiro, Yoshiki Hirooka, Atsushi Enomoto, & Masahide Takahashi

Researcher contact details:

Professor Atsushi Enomoto
Department of Pathology, Graduate School of Medicine, Nagoya University
Email: enomoto@iar.nagoya-u.ac.jp

Nagoya University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.